Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions by �쑄�긽�꽑
Research article
436	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 116	 	 	 Number 2	 	 	 February 2006
Anaerobic killing of mucoid Pseudomonas 
aeruginosa by acidified nitrite derivatives 
under cystic fibrosis airway conditions
Sang Sun Yoon,1 Ray Coakley,2 Gee W. Lau,3 Sergei V. Lymar,4 Benjamin Gaston,5,6  
Ahmet C. Karabulut,1 Robert F. Hennigan,7 Sung-Hei Hwang,1 Garry Buettner,8 Michael J. Schurr,9 
Joel E. Mortensen,10 Jane L. Burns,11 David Speert,12 Richard C. Boucher,2 and Daniel J. Hassett1
1Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.  
2Cystic Fibrosis Pulmonary Research and Treatment Center and Department of Pulmonary Biology, University of North Carolina,  
Chapel Hill, North Carolina, USA. 3Pulmonary Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.  
4Department of Chemistry, Brookhaven National Laboratory, Upton, New York, USA. 5Department of Cell Biology, University of Cincinnati  
College of Medicine, Cincinnati, Ohio, USA. 6Department of Pediatric Critical Care, University of Virginia School of Medicine, Charlottesville, Virginia, USA. 
7Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York, USA. 8Department of Chemistry,  
University of Iowa, Iowa City, Iowa, USA. 9Department of Microbiology, Tulane University, New Orleans, Louisiana, USA. 10Department of Pediatrics,  
Pathology and Laboratory Medicine, Children’s Hospital, Cincinnati, Ohio, USA. 11Infectious Diseases Section, Children’s Hospital and Regional Medical Center, 
Seattle, Washington, USA. 12Department of Pedriatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Mucoid,	mucA	mutant	Pseudomonas aeruginosa	cause	chronic	lung	infections	in	cystic	fibrosis	(CF)	patients	
and	are	refractory	to	phagocytosis	and	antibiotics.	Here	we	show	that	mucoid	bacteria	perish	during	anaero-
bic	exposure	to	15	mM	nitrite	(NO2–)	at	pH	6.5,	which	mimics	CF	airway	mucus.	Killing	required	a	pH	lower	
than	7,	implicating	formation	of	nitrous	acid	(HNO2)	and	NO,	that	adds	NO	equivalents	to	cellular	mol-
ecules.	Eighty-seven	percent	of	CF	isolates	possessed	mucA	mutations	and	were	killed	by	HNO2	(3-log	reduc-
tion	in	4	days).	Furthermore,	antibiotic-resistant	strains	determined	were	also	equally	sensitive	to	HNO2.	
More	importantly,	HNO2	killed	mucoid	bacteria	(a)	in	anaerobic	biofilms;	(b)	in	vitro	in	ultrasupernatants	
of	airway	secretions	derived	from	explanted	CF	patient	lungs;	and	(c)	in	mouse	lungs	in	vivo	in	a	pH-depen-
dent	fashion,	with	no	organisms	remaining	after	daily	exposure	to	HNO2	for	16	days.	HNO2	at	these	levels	
of	acidity	and	NO2–	also	had	no	adverse	effects	on	cultured	human	airway	epithelia	in	vitro.	In	summary,	
selective	killing	by	HNO2	may	provide	novel	insights	into	the	important	clinical	goal	of	eradicating	mucoid	
P. aeruginosa	from	the	CF	airways.
Introduction
Pseudomonas aeruginosa is an important pathogen that is most 
refractory to therapy when it forms biofilms in the airways of 
cystic fibrosis (CF) patients. CF is caused by mutations in the CF 
transmembrane conductance regulator (CFTR) gene. Although 
airway CFTR functions predominantly as an epithelial Cl– chan-
nel, it serves to coordinate Na+ absorption and Cl– secretion to 
produce sufficient airway surface liquid (ASL) for normal mucus 
clearance (1). Without functional CFTR, isotonic hyperabsorp-
tion of ASL, driven by enhanced absorption of Na+ via the epi-
thelial sodium channel, results in ASL depletion, mucus con-
centration, and the formation of stagnant mucus plaques (2). 
Another feature of CF ion transport dysfunction is that the ASL 
may be acidified (pH <6.5) due to defective bicarbonate (HCO3–) 
ion transport (3).
Two simultaneous seminal studies have recently indicated 
that the mucus layer lining the CF airway lumen is anaerobic 
and that robust biofilm formation by P. aeruginosa occurs under 
such conditions (4, 5). The anaerobic nature of the CF airway 
mucus reflects the oxygen-consumptive activities of airway epi-
thelia, P. aeruginosa, and other opportunistic pathogens as well 
as neutrophils that combat infection. As chronic CF lung disease 
progresses, mucoid, alginate-overproducing strains emerge and 
become the predominant form (6). Mucoid P. aeruginosa biofilms 
are inherently resistant to antibiotics (7) and phagocytic neutro-
phils (8). Although several gene products have been reported to 
stimulate either a genotypic or phenotypic switch to the mucoid 
form, the best-characterized mechanism of mucoid conversion 
in CF isolates is via mutations in mucA, encoding an anti-s fac-
tor (9). Without MucA, the extracytoplasmic s factor AlgT(U) 
transcribes genes involved in alginate biosynthesis. Mutations 
in mucA and mucoid conversion can be triggered in vitro when 
biofilms are treated with H2O2 at levels similar to those gener-
ated by human neutrophils (10), professional phagocytes that 
are abundant in the CF airways. Approximately 84% of mucoid 
CF isolates (n = 53) in the US have been shown to possess mucA 
mutations (11). In contrast, mucoid mucA mutant bacteria are 
found in approximately 44% of the CF isolates from Australia, 
although the number of patients studied was substantially less 
than in the US cohort (12).
An important link between mucoidy and anaerobic metabo-
lism by P. aeruginosa was identified in a study demonstrating that 
mucoid organisms were incapable of reversion to their nonmucoid, 
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antibiotic- and phagocyte-susceptible counterparts during anaero-
bic growth (13), results that were confirmed in 2002 by Wyckoff et 
al. (14). Recently, Worlitzsch and colleagues reported that anaero-
bic ASL favored production of alginate by P. aeruginosa (4). P. aeru-
ginosa is capable of robust anaerobic growth by respiration using 
nitrate (NO3–) or nitrite (NO2–) as terminal electron acceptors (5). 
NO3– and NO2– are present in CF ASL (15–18)	and sputum (19), 
and NO3– levels have been estimated as high as 600 μM (19), con-
centrations permissive for anaerobic P. aeruginosa growth in vitro 
and in vivo (20). Still, during anaerobic growth, P. aeruginosa must 
control the levels of a toxic intermediate of NO2– reduction, NO, by 
synthesis of protective NO reductase (NOR) (5). This requirement 
was demonstrated by the observation that overproduction of NO 
by anaerobic P. aeruginosa biofilms lacking the rhl quorum sensing 
circuit caused a metabolic suicide of these bacteria, an event that 
was prevented by a NO scavenger (21).
NO is also produced in normal airway epithelia by 3 differ-
ent NO synthases (NOSs). Neuronal NOS and eNOS isoforms 
are constitutively expressed. The third isoform (iNOS) is also 
constitutively expressed in the airways but is inducible and 
upregulated in response to proinflammatory cytokines and 
bacterial LPS (22). Specifically, the iNOS2 class of enzymes con-
tributes most effectively to the antimicrobial armament of the 
airway. However, in chronic CF, iNOS2 activity is significantly 
reduced (23), and this defect is thought to contribute to the per-
sistence of airway P. aeruginosa populations.
Herein we describe a novel approach to killing mucoid P. aeru-
ginosa. This is attributable in part to the organism’s extremely 
low nitrite reductase (NIR) and NOR activity, a defect dependent 
upon mucA mutations. We investigated the mechanism of this 
effect in in vitro human studies and explored the therapeutic 
potential of NO2– in both human and mouse safety and mouse 
in vivo efficacy studies. Treatment of mucoid, mucA mutant bac-
teria with NO2– at pH 6.5 under anaerobic conditions, similar 
to conditions within mucopurulent secretions in the airways of 
CF patients, led to the death of these organisms. Ultimately, this 
observation may lead to the development of novel therapies for 
CF patients colonized with mucoid P. aeruginosa.
Results
CF airway luminal secretion pH is slightly acidic. The goal of this study 
was to test the hypothesis that mucoid P. aeruginosa are far more 
adept at growing during anaerobic respiration than nonmucoid 
bacteria, which is based on the fact that mucoid bacteria emerge 
and predominate during the chronic stages of CF airway disease. 
However, to accurately test this hypothesis, we wanted to assure 
that our medium pH was identical to that of the CF airway mucus. 
Previous in vitro studies suggest that the pH of the CF ASL is less 
than 6.5 (3). However, it is conceivable that the pH of mucopuru-
lent secretions within CF airways might differ in vivo. Hence, we 
performed in situ pH measurements of luminal secretions from 
freshly explanted lungs removed from 9 different CF patients at 
the time of transplantation. The pH of the secretions was slightly 
lower than what was observed in vitro: 6.45 ± 0.03 in segmental 
airways and somewhat lower in more distal subsegmental bronchi 
(6.39 ± 0.04; Figure 1). These results guided our selection of pH 6.5 
for subsequent experiments.
Mucoid, mucA mutant bacteria are sensitive to acidified NO2–. Based 
upon the slightly acidic pH measurements of segmental and sub-
segmental bronchi from CF transplant patients discussed above, 
we elected to grow various well-characterized P. aeruginosa strains 
at pH 6.5 under strict	anaerobic conditions. Thus, upon anaero-
bic culture of P. aeruginosa at pH 6.5 with 15 mM NO3– (electron 
acceptor), mucoid P. aeruginosa strain FRD1 grew more slowly 
than nonmucoid strains PAO1 and FRD1/pmucA. Strain FRD1 
is the best characterized mucoid, mucA mutant derived from a 
CF patient (24). However, no difference in viability patterns 
was observed (Figure 2A). Using 15 mM NO2–, however, mucoid 
FRD1 was killed at a rate of approximately 90% per day, while 
nonmucoid strains PAO1 and FRD1/pmucA remained viable over 
the 4-day incubation (Figure 2B).
After discovering this unique NO2– sensitivity of mucA mutant 
strain FRD1, we also found that NO2– killed these bacteria more 
effectively at a lower pH (Figure 2C), while little or no killing was 
observed in strain FRD1/pmucA at pH 6.0–7.5 (Figure 2C).
To test whether NO2– killing of mucoid bacteria occurs in 
the presence of nonmucoid bacteria, mucoid and nonmucoid 
P. aeruginosa were mixed and treated with 15 mM NO2– anaer-
obically. Strain FRD1 consistently lost viability at 3 different 
bacterial test ratios, while nonmucoid FRD1/pmucA maintained 
viability (Figure 2D).
We next characterized the dose-effect relationship between NO2– 
concentration and killing of mucoid bacteria. Figure 2E shows 
that 90–95% of the bacteria were killed by 15 mM NO2– and the 
LD50 was approximately 3 mM NO2– after 24 hours. The remaining 
organisms did not develop resistance to NO2– when we extended 
our study to 12 days (Figure 2F), demonstrating that all organisms 
were killed during this time period.
Other mucoid, mucA mutant CF isolates are also sensitive to NO2–. 
To test whether NO2– sensitivity is a trait of all mucA mutant 
mucoid CF isolates, the mucA genes of 94 mucoid clinical iso-
lates recovered from a variety of CF clinics in the US and Canada 
were sequenced. Of 94 strains, 82 harbored mucA mutations, 
leading to either premature termination of translation (88%) 
or a loss of the stop codon (12%), thereby confirming previous 
findings (13) that mucA mutations are the major reason for 
mucoid conversion in CF isolates (Figure 3 and Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI24684DS1). The most abundant mutations were 
Figure 1
The pH of CF airway mucus is slightly acidic. In situ pH measure-
ments of mucopurulent airway secretions from CF airways were 
made as described in Methods. Each measurement is presented 
as an individual data point in the scatter plots. The mean ± SEM is 
shown below each panel.
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single-bp deletions that resulted in a frame shift leading to pre-
mature termination of translation at bp 441 (the wild-type mucA 
gene is 585 bp; see Supplemental Table 1 for a detailed break-
down of mucA mutations in each strain). Consistent with the 
results of Martin et al. (9), approximately 13% of mucoid isolates 
had a wild-type mucA allele, indicating the presence of other 
mechanisms or mutations allowing for mucoid conversion. 
Upon anaerobic treatment with 15 mM NO2– at pH 6.5, almost 
all of the mucA mutant mucoid isolates (78 of 82 strains) showed 
increased susceptibility to NO2–, with 74% killed by more than 
2 logs relative to the mean of the nonmucoid MucA-proficient 
organisms (Figure 3). Importantly, 4 strains that were deemed 
antibiotic resistant were still sensitive to anaerobic treatment of 
acidified NO2– (Figure 3, arrows). Out of 12, however, 8 mucoid 
isolates with a wild-type mucA allele were resistant to acidified 
NO2–. These results suggest that NO2– sensitivity is likely caused 
by mucA mutations and not by cellular processes associated with 
alginate overproduction.
In a separate longitudinal study using P. aeruginosa strains iso-
lated from 5 different young CF patients, we consistently detected 
mucoid P. aeruginosa as the patient aged, a hallmark of chronic 
infection (Table 1). As predicted, initial airway colonization of each 
patient was by nonmucoid 
P. aeruginosa. Most impor-
tantly, however, mucoid 
variants that were detected 
in patients A, B, C, and D 
possessed mutated mucA 
genes and were all killed by 
15 mM NO2– (1.9–3.1 logs). 
These results indicate that 
the genotypic and pheno-
typic switch to the mucoid 
form that is sensitive to 
NO2– treatment can occur in 
patients less than 3 years of 
age (see patient C).
mucA mutations are respon-
sible for NO2– sensitivity. The 
above results suggest that 
mucA mutations could be 
responsible for the enhanced 
sensitivity to NO2–. Since 
mucA mutant bacteria over-
produce alginate, we initi-
ated experiments to test 
whether NO2– sensitivity is 
caused by mucA mutations 
and not by alginate pro-
duction. An isogenic PAO1 
mucA mutant, PDO300, 
whose intact mucA allele was 
replaced with that of strain 
FRD1 (mucA22) was also 
sensitive to NO2– (Table 2). 
Two FRD1 derived nonmu-
coid mutants [ΔalgD, lacking 
GDP-mannose dehydroge-
nase, and ΔalgT(U), lacking 
AlgT(U)] were equally sensi-
tive to killing by NO2– (Table 2). We next tested whether NO2– 
also killed mucB, mucD, and algW mutants of strain PAO1. Other 
than mucA, the aforementioned genes are the only reported loci 
that, when inactivated, allow for mucoid conversion in P. aerugi-
nosa (25–27). In contrast to mucA mutant bacteria, these mutants 
were not sensitive to NO2– (Table 2). Most critically, 5 nonmu-
coid revertants of mucoid strains were still sensitive to HNO2 (see 
Table 2). Therefore, our results suggest that NO2– sensitivity is 
MucA- and not alginate dependent. Finally, the LD50 of NO2– for 
sensitive strains was almost identical to that for FRD1 (Figure 2E), 
suggesting that the rate at which these organisms were killed by 
NO2– was similar to that of strain FRD1.
HNO2 is required for killing of mucA mutant bacteria; NO and other 
HNO2-derived intermediates are responsible. Collectively, our results 
indicate that the acidic pH approximately 6.5 of the CF airway 
mucus promotes the generation of NO2– derivative(s) that selec-
tively kill mucA mutant P. aeruginosa. Undoubtedly, these deriva-
tives originate from nitrous acid (HNO2, pKa = 3.3, where pKa is 
the negative logarithm of the equilibrium constant Ka), whose 
equilibrium concentration increases with medium acidity. We 
tested this conjecture by exposing strain FRD1 to 2 different cul-
ture conditions with identical HNO2 concentrations of approxi-
Figure 2
Mucoid P. aeruginosa FRD1 is selectively killed by NO2– in a pH-dependent manner. Anaerobic growth of 
P. aeruginosa strains at pH 6.5 using 15 mM NO3– or NO2– as a terminal electron acceptor. Aerobic overnight 
suspensions of PAO1, FRD1, and FRD1/pmucA were diluted 100-fold for the main anaerobic culture with 
NO3– (A) or NO2– (B). CFUs were enumerated each day and plotted as linear (A) and logarithmic (B) graphs. 
(C) NO2– sensitivity versus pH. FRD1 or FRD1/pmucA were seeded onto LB agar buffered at the indicated 
pH value. After placing a filter disk containing 10 μl of 1 M NO2–, the plates were incubated anaerobically for 
48 hours and scanned for viewing the zone of killing. To support anaerobic growth, 15 mM NO3– was included 
in the media. (D) Mucoid strain FRD1 (gray bars) and nonmucoid FRD1/pmucA (black bars) were incubated 
together at the indicated ratios (FRD1/pmucA:FRD1) for 5 days in the presence of 15 mM NO2–, pH 6.5, after 
which CFUs were determined. *P < 0.001 versus CFU in the initial inoculum. (E) Dose-response killing of 
mucoid strain FRD1 by NO2–. Bacteria were suspended in LB (pH 6.5) with various amounts of NO2– for 24 
hours under anaerobic conditions. Survival against NO2– is presented as the percentage of CFU relative to 
that in initial inoculum. (F) Long-term anaerobic exposure of mucoid strain FRD1 to 15 mM NO2– at pH 6.5. All 
experiments were performed in triplicate and presented as mean ± SEM.
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mately 10 μM (pH 6.5, 15 mM NO2–, and pH 5.5, 1.5 mM NO2–). 
Under both conditions, equal killing of bacteria was observed, 
supporting the notion that formation of HNO2 is a prerequi-
site for killing mucoid P. aeruginosa (Figure 4A). Both mucoid 
FRD1 and nonmucoid FRD1/pmucA 
maintained viability at these pH values 
when no NO2– was added (Figure 4A, 
left side of each plate).
At such low concentrations, HNO2 is 
unlikely to directly inflict lethal lesions 
because it is relatively unreactive and 
would revert to NO2– upon penetrat-
ing bacterial membrane and entering 
the neutral cytoplasm. However, HNO2 
is unstable toward disproportionation 
that slowly generates NO and NO3–. 
Consistent with this chemistry, our 
results revealed that NO accumulated 
upon addition of NO2– to Luria-Bertani 
broth (LB) at pH 6.5 (Figure 4B). After a 
rapid rise, NO levels plateau at approxi-
mately 490 nM, which corresponds to 
the decomposition of a small fraction of 
added NO2– and indicates that its decom-
position is impeded by accumulating 
NO. The addition of the stoichiomet-
ric NO scavenger, 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl-
3-oxide (carboxy-PTIO), temporarily 
depleted NO, but the NO level was promptly restored following 
scavenger consumption. This dynamic behavior directly bears 
on the bactericidal action of acidified NO2– and is explicable by 
the well-established 2-step HNO2 decomposition mechanism 
(Supplemental Table 2). In the first reversible step, a pair of NO 
and NO2• radicals are generated (Equation 1), but this reaction 
is so strongly shifted to the left that only 3 nM each of NO and 
NO2• are present at equilibrium.
Equation 1
However, the second dimerization/hydrolysis step (Equation 2) 
removes NO2•, thus shifting the equilibrium of Equation 1 to 
the right and leading to accumulation of NO to a level at which 
the reverse NO + NO2• reaction in Equation 1 outcompetes the 
NO2• dimerization/hydrolysis, making further NO accumula-
tion extremely slow.
Equation 2
This chemistry is amenable to a kinetic analysis by computer 
simulation (ref. 28 and Supplemental Table 2) revealing that 
the initial rate of NO accumulation of approximately 4 μM/h 
decreases by more than 3 orders of magnitude when NO reaches 
approximately 500 nM; notably, identical NO accumulation pro-
files are predicted for 15 mM NO2–, pH 6.5 and 1.5 mM NO2–, 
pH 5.5, thereby explaining the results in Figure 4A. As observed 
in Figure 4B, the simulations predict 90% NO depletion in 25 
minutes upon the addition of 200 nM carboxy-PTIO and clearly 
show that out of the 3 intermediates of NO2– decomposition 
(HNO2, NO2•, and NO), only NO reacts with carboxy-PTIO. If 
Figure 3
HNO2 sensitivity of 94 different mucoid CF clinical isolates of P. aeru-
ginosa. Aerobic starter cultures of each strain were diluted 100-fold in 
LB (pH 6.5) supplemented with 15 mM NO2–. The CFU in the inocu-
lum versus that after a 4-day anaerobic incubation were determined. 
The values for log10 [CFUafter 4 days/CFUinoculum] were calculated and 
are plotted as the viability index. The mucA gene of each isolate was 
sequenced, and mucoid strains with wild-type mucA alleles and those 
harboring mucA mutation were shown at left and right, respectively. 
Arrows indicate clinical isolates that were found to be highly resistant 
to amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin, genta-
mycin, imipenem, and tobramycin.
Table 1
Age-dependent emergence of mucA mutant P. aeruginosa from 5 different CF patients and 
sensitivity of each isolate to acidified NO2–
Patient	 Age	(yr)	 Mucoid	 mucA mutation	 Viability	index	 Note
A 2.8 NM No 0.72 First P. aeruginosa colonization
 4.5 NM No 0.13  
 6.0 M Yes, stop at 441 –3.1 First mucoid P. aeruginosa isolation
B 1.2 NM No 0.21 First P. aeruginosa colonization
 3.0 NM No 1.07  
 5.3 M No –3.14 First mucoid P. aeruginosa isolation
 5.5 M Yes, stop at 351 –2.93 Mucoid P. aeruginosa isolation
C 0.5 NM No 1.3 First P. aeruginosa colonization
 2.5 NM No 0.15  
 2.9 M Yes, stop at 441 –1.9 First mucoid P. aeruginosa isolation
D 6.0 NM No 0.13 First P. aeruginosa colonization
 7.6 NM No 1.13  
 10.7 M Yes, stop at 441 –2.88 First mucoid P. aeruginosa isolation
E 2.2 NM No 1.2 First P. aeruginosa colonization
 5.3 NM No 1.09  
 5.7 M No 0.9 First mucoid P. aeruginosa isolation
The mucA genes of 3–4 sequential isolates from each patient were sequenced and viability index 
of all isolates were determined as described in Figure 3. Age provided is the age at which bacterial 
samples were isolated. NM, nonmucoid; M, mucoid.
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HNO2 reacted, the addition of carboxy-PTIO would cause no 
change in NO concentration. If NO2• were reactive, we would 
observe a sharp 200-nM increase in the NO concentration upon 
carboxy-PTIO addition. Thus, carboxy-PTIO is a selective NO 
scavenger in our system.
This analysis naturally suggests that NO is involved in the 
microbicidal action of HNO2. It also allows an experimentally 
verifiable prediction that carboxy-PTIO should have a strong 
protective effect when added at millimolar concentrations. As 
shown in Figure 4C, such protection is indeed observed. The 
computer modeling analysis shows that, under the conditions 
in Figure 4C, carboxy-PTIO will persist in solution for several 
weeks, keeping NO concentrations at picomolar levels. Similar-
ly protective effects were observed with another NO scavenger, 
deoxyhemoglobin (Figure 4C and ref. 29). These experiments 
therefore establish that NO was at least potentially 1 direct 
or indirect contributor to the bactericidal activity of acidified 
NO2–. This conclusion is strongly supported by the observation 
that strain FRD1, but not FRD1/pmucA, was killed when an 
NO/argon gas mixture was bubbled into the bacterial suspen-
sion (Figure 4D); a 380-nM solution concentration of NO main-
tained in this experiment was comparable to that generated by 
15 mM NO2– at pH 6.5 (Figure 4B). In contrast, both strains 
maintained viability when treated with argon gas.
Although a link between NO depletion and the decrease of bac-
tericidal activity of acidified NO2– clearly exists, it is premature to 
conclude that NO is per se the toxic agent in this system or the 
only toxic agent. NO depletion, whether through the action of 
exogenous carboxy-PTIO or endogenous NOR activity, may inhib-
it several downstream reactions by which HNO2 may kill mucoid 
P. aeruginosa. These reactions alter the reaction dynamics modeled 
in buffer alone and may ultimately prove relevant to the observed 
bactericidal effect of HNO2. For example, high NO levels promote 
formation of a strong nitrosating intermediate, N2O3 in Equation 1, 
which can cause “nitrosative stress” by modifying the function 
of proteins (30). Additionally, NO can react with iron and sulfur 
species in bacteria to form bioactive S-nitrosothiols (31) that may 
be potent in killing mucoid P. aeruginosa, an intriguing possibility 
given that S-nitrosothiol levels are low in the CF airway.
Although we strived for strictly anaerobic condi-
tions, even remotely low levels of O2 could be problem-
atic because of the attendant generation of O2–, which 
combines with NO to form peroxynitrite (ONOO–), an 
extremely bactericidal species (32, 33). We used a sodAsodB 
mutant, devoid of iron- and manganese-cofactored 
superoxide dismutase. As such, it is extremely sensitive 
to even endogenously generated O2– (34). Were trace 
oxygen to be reduced to O2– in the sodAsodB mutant 
in the presence of NO, then ONOO– would form and 
kill the sodAsodB mutant much more rapidly than was 
observed in wild-type organisms. Figure 4E shows that 
the sodAsodB mutant of strain PAO1 was not sensitive 
to HNO2 under anaerobic conditions. In contrast and 
as expected, under aerobic conditions, the sodAsodB 
mutant was more sensitive to HNO2 (Figure 4E, com-
pare lines shown with diamonds). These results indicate 
that ONOO– is not formed in our anaerobic cultures 
and that bacterial killing is not due to this species.
Mucoid mucA mutant bacteria harbor low anaerobic 
NOR and NIR activity. Our next goal was to define the 
molecular basis of HNO2 sensitivity of mucoid mucA mutant 
bacteria. We first measured the activity of enzymes involved 
in P. aeruginosa anaerobic respiration, including NO3– reduc-
tase (NAR), NIR, and NOR (Figure 5A). Strain FRD1 possessed 
approximately 3.7-fold greater NAR activity compared with 
nonmucoid FRD1/pmucA and PAO1. However, strain FRD1 pos-
sessed only 4% and approximately 20% the NIR and NOR activi-
ty, respectively, of strain PAO1 (Figure 5A). Interestingly, FRD1/
pmucA possessed approximately 2-fold higher NO consuming 
activity compared with strain PAO1 (Figure 5A), suggesting a 
positive correlation of NOR activity with the presence of mul-
tiple copies of wild-type MucA. The reduced NOR activity in 
strain FRD1 explains in part the very limited capacity for remov-
al of NO by this organism and, hence, its greater sensitivity to 
purified NO. The lack of NIR activity in strain FRD1 explained 
the failure of NO2– to support anaerobic growth of this strain. 
In addition, the low NIR activity in strain FRD1 led to the con-
stancy of HNO2 levels in the culture medium and the attendant 
increase in NO levels compared with strains that metabolize 
NO2–. Strikingly, there was no significant loss of NO2– from the 
culture medium after 4 days at pH 6.5, suggesting that there was 
no biological reduction of NO2– in strain FRD1 and 16 different 
mucoid, mucA mutant CF isolates assessed for NO2– sensitivity 
(Supplemental Table 1) and remaining NO2– levels (Figure 5B). 
Moreover, these data also demonstrate that NO formed from 
HNO2 at this pH and NO2– concentration in the presence of 
mucA mutant organisms was virtually all recycled to NO2–, sup-
porting a mechanism for NIR-deficient mutant bacteria kill-
ing that involves NO oxidation and formation of NO+ equiva-
lents. These data confirm the lack of respiratory NIR activity 
in mucoid, mucA mutant P. aeruginosa (Figure 5B). In contrast, 
supernatants of wild-type strain PAO1 and FRD1/pmucA had 
little or no media NO2– remaining (Figure 5B).
Finally, because NOR activity was significantly reduced in 
mucoid bacteria, we postulated that mucoid organisms com-
pletely devoid of NOR activity would be more sensitive to HNO2. 
Figure 5C demonstrates that a norCB mutant of strain FRD1 
was approximately 10-fold more sensitive to acidified NO2– than 
were wild-type organisms.
Table 2
Correlation between mucA mutations and NO2– sensitivity
Strain	 Mucoid	 mucA	mutation	 Viability	index	 LD50
PDO300 (PAO1 mucA22) M Yes –2.4 4.1 (± 0.2)
PAO1 mucB::Tcr M No 0.45 N/A
PAO1 mucD::Tcr M No 0.39 N/A
PAO1 algW::Tcr M No 0.57 N/A
FRD1 NM Yes –3.84 2.8 (± 0.18)
FRD1 algD::Tn501 NM Yes < –3.48 2.5 (± 0.1)
FRD1 algT(U)::Tn501 NM Yes –3.95 2.45 (± 0.15)
Clinical isolate 35 NM Yes < –3.71 3.1 (± 0.08)
Clinical isolate 37 NM Yes < –4.12 2.2 (± 0.1)
Clinical isolate 38 NM Yes < –4.54 2.55 (± 0.34)
Clinical isolate 40 NM Yes < –3.87 2.6 (± 0.2)
FRD1 and P. aeruginosa clinical isolates 35, 37, 38, and 40 are nonmucoid (NM) 
revertants from the original mucoid (M) isolates (see Supplemental Table 1). Viability 
index was calculated as described in Figure 3. The LD50 of NO2– was determined from 
a graph correlating the percent survival of strains after 24 hours of exposure to acidi-
fied NO2– ranging from 1–5 mM (see Figure 2E).
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HNO2 kills mucoid P. aeruginosa in in vitro anaerobic biofilms and 
fresh sputum isolates from CF patients. To explore the potential clini-
cal application of HNO2 in the treatment of mucoid P. aeruginosa 
infections in chronic CF patients, we first tested the effect of 
NO2– on the viability of biofilm bacteria. Anaerobic biofilms of 
strains FRD1 and FRD1/pmucA were grown for 1 day in media 
containing NO3–, which supports anaerobic respiration. Since 
mucoid strain FRD1 lacks a flagellum (35), a surface appendage 
that is critical for P. aeruginosa biofilm initiation (36), strain FRD1 
formed much weaker biofilms than those of flagellated FRD1/
pmucA (Figure 6, compare A and B). When the FRD1 biofilm was 
treated with NO2– at pH 7.5 for 2 days, no difference in biofilm 
structure and cell viability was observed relative to control bio-
films. In contrast, nearly complete death of biofilm organisms was 
observed after a 2-day incubation with NO2– at pH 6.5 (Figure 6A, 
top right). In biofilms of FRD1/pmucA, however, resistance to 
acidified NO2– was clearly evident (Figure 6B).
We next monitored the effect of HNO2 on the killing of spu-
tum isolates from CF patients. Sputum isolates CF1, -2, -3, and 
-4 harbored nearly 100% mucoid mucA mutant bacteria, while the 
CF5 isolate harbored only nonmucoid MucA-proficient P. aeru-
ginosa (Figure 6C). To minimize loss of the properties acquired 
in vivo, these isolates were passed only once in L-broth and 
immediately assayed for anaerobic NO2– sensitivity. When these 
isolates were exposed to 15 mM NO2– at pH 6.5 under anaerobic 
conditions for 1 day, a sharp decrease in viability was observed 
in the mucoid mucA mutant isolates. Again, the inherent util-
ity of these isolates was that they were freshly isolated from CF 
patients and were not from long-term frozen stocks derived 
from CF patients. These results clearly indicate that high levels 
of HNO2 selectively kill mucoid mucA mutant P. aeruginosa.
HNO2 kills mucoid P. aeruginosa in a sterile ultrasupernatant derived 
from explanted CF lungs and in mouse airways. Next, we determined 
whether mucoid strain FRD1 could be killed by HNO2 in ster-
ile ultrasupernatants (pH 6.24) of CF airway secretions derived 
from explanted CF lungs. This reagent arguably represents the 
best medium to investigate P. aeruginosa in the context of bacte-
rial growth and the effects of HNO2 ex vivo. Figure 7A shows that 
mucoid bacteria were actually killed faster by HNO2 in the CF 
ultrasupernatants than in L-broth (Figure 2B).
Figure 4
NO is involved in killing of mucoid mucA mutant bacteria. (A) Anaerobic sensitivity of P. aeruginosa under conditions allowing for the formation 
of identical NO levels. Bacteria were incubated anaerobically for 4 days with or without 15 mM and 1.5 mM NO2– at pH 6.5 and 5.5, respectively. 
To enumerate viable cells, 10 μl of serial dilutions were spotted on LB agar plates and incubated at 37°C for 15 hours. The left and right side of 
each plate represent control and NO2–-exposed bacteria. (B) NO levels generated by 15 mM NO2– (pH 6.5) over time. Carboxy-PTIO (200 nM) 
was added, and the stoichiometric decrease in NO signal is shown. The coefficient of determination (r2) between NO concentration and electric 
current (pA) was 0.9997. (C) Effects of NO scavengers on protection of FRD1 from acidified NO2–. Carboxy-PTIO (5 mM) or deoxyhemoglobin 
(0.5 mM) was added in the initial media (LB, pH 6.5, 15 mM NO2–). (D) Toxicity of NO toward FRD1 and FRD1/pmucA in LB at pH 6.5. NO (333 
parts per million) balanced with argon was continuously bubbled for 24 hours anaerobically and viable bacteria were subsequently enumerated. 
Results of 4 experiments are shown. In NO-treated FRD1, differences in CFU between 2 time points were statistically significant (*P < 0.01). 
(E) P. aeruginosa PAO1 (circles) and isogenic sodAsodB double mutants (diamonds) were grown in LB, pH 6.5, containing 15 mM NO2– under 
aerobic (2 days, dotted lines) and anaerobic (4 days, solid lines) conditions. CFUs were measured daily and plotted in logarithmic scale. For 
aerobic samples, strains were grown with vigorous shaking (300 rpm).
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Next, we measured NO levels generated from HNO2 dispro-
portionation in ASL collected from primary CF airway epithelia. 
Figure 7B indicates that NO was produced in CF ASL at lev-
els even greater (562 nM) than those generated in LB at pH 6.5 
(489 nM, Figure 4B). The higher levels of NO produced upon 
addition of NO2– in this milieu were likely due to the lower pH 
of the sample (6.43 versus 6.5).
We then determined the efficacy of HNO2 to kill strain FRD1 
in a P. aeruginosa chronic lung infection model. Currently, there 
is no animal model for the anaerobic biofilm mode of CF airway 
disease or a CF animal that acquires spontaneous P. aeruginosa 
infections. However, CD1 mice inoculated with agarose beads 
impregnated with bacteria have been useful for studying chronic 
lung infection by P. aeruginosa (37). Consistent with our in vitro 
results, mucoid FRD1, but not nonmucoid FRD1/pmucA, were 
decreased more than 2 logs at pH 6.5 and more than 3 logs at 
pH 5.5 by HNO2– in vivo (Figure 7C). Because NO concentra-
tions derived from acidified NO2– are 10-fold greater with a 
reduction of 1 pH unit, our results are consistent with classical 
NO2– reduction chemistry. Furthermore, organisms that were 
recovered from the mouse airways after NO2– exposure were 
still sensitive to NO2– in vitro (data not shown), although these 
results do not clearly indicate that NO itself within the bacterial 
cytoplasm is the toxic species.
We also addressed whether long-term treatment with HNO2 
produced progressively decreasing airway titers of mucoid, mucA 
mutant bacteria. NO2– was instilled on a daily basis in mice infect-
ed with mucoid organisms for a period of 16 days. Figure 7D 
shows that there was no bacteria detected in mice treated for 16 
days with HNO2, while buffer control mice still harbored nearly 
104 mucoid organisms per lung.
To address the possibility that acidified HNO2 can kill mucoid 
mucA mutant bacteria in the presence of nonmucoid bacteria in 
vivo (similar to the results obtained in vitro in Figure 2D), com-
petitive index (CI) experiments were performed. Figure 7E demon-
strates that the CI was only approximately 0.2 for mucoid, mucA 
mutant strain FRD1 relative to its complemented strain, FRD1/
pmucA, which was approximately 1.0.
NO2– does not elicit adverse effects on airway epithelia in vitro. The 
clinical utility of NO2– as a treatment would be diminished if 
it exerted significant toxic or adverse effects on airway epithe-
lia. Therefore, we tested the effect of NO2– on cell viability and 
function of cultured airway epithelia. Furthermore, since NO2– 
may elicit a proinflammatory response that would be undesir-
able in the CF airways, and NO has been reported to increase 
IL-8 gene transcription in a lung epithelial cell line (38), we also 
tested whether NO2– induces IL-8 release from cultured airway 
epithelia. Aerosolization, a potential therapeutic delivery route 
for NO2– to the CF airways, would deliver it in small volumes on 
the epithelial surface. To mimic this situation in vitro, we added 
a low volume (2 μl) of test solution containing various concen-
trations of NO2– to the apical surface of CF airway epithelia 
at pH 6.5. Exposure to concentrations as high as 20 times the 
dose required to kill mucoid mucA mutant P. aeruginosa exerted 
no cytotoxicity toward CF airway epithelia after 24 hours, as 
determined by lactate dehydrogenase release (Figure 8A). We 
performed such experiments because aerosol exposure of any 
effective agent, regardless of treatment, requires that signifi-
cantly higher concentrations (about 25-fold) of stock solution 
be used so that appropriate doses are administered efficiently 
to the areas of interest.
In CF culture preparations mounted in Ussing chambers, 
basal transepithelial short circuit current (Isc) was not affected 
by NO2– exposure (Figure 8B). Further, 15 mM NO2– failed to 
affect amiloride-sensitive Isc (control, 15.4 ± 1.4 μA/cm2; treat-
ed, 15.7 ± 1.7 μA/cm2; P = 0.92) and UTP-activated Isc (control, 
17.7 ± 3.0 μA/cm2; treated, 18.1 ± 3.3 μA/cm2; P = 0.92). Consis-
tent with these data, 15 mM NO2– did not alter transepithelial 
water flux (Jv) in the same cultures (Figure 8C) or trigger IL-8 
release over 24 hours in CF epithelia (Figure 8D). Finally, we 
performed preliminary studies of the durability of NO2– on CF 
Figure 5
Significantly reduced NIR and NOR activities in mucA mutant P. aeru-
ginosa account for the sensitivity to HNO2. (A) Relative activities of 
NAR, NIR, and NOR in FRD1 (lane 2) and FRD1/pmucA (lane 3), 
normalized to that of the well-characterized laboratory strain PAO1 
(lane 1). Each assay was performed in triplicate, and the mean ± SEM 
is presented. A schematic diagram of the P. aeruginosa anaerobic 
respiration pathway is shown. Bacteria were grown in LB (pH 6.5) con-
taining 100 mM NO3– for 15 hours under anaerobic conditions. (B) 
P. aeruginosa strains were incubated anaerobically in LB containing 
15 mM NO2–, pH 6.5. After 4 days at 37°C, NO2– levels were mea-
sured in triplicate. All other mucA mutant clinical isolates were among 
those described in Supplemental Table 1. For the media-only control, 
no bacteria were used. ND, not detected. (C) Anaerobic sensitivity of 
FRD1 and FRD1 norCB mutant exposed to NO2– at pH 6.5. Experi-
mental conditions were identical to those used in Figure 2B. Δ, deletion 
of a specific gene. *P < 0.01 versus FRD1.
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airway surfaces. We found that the half life of NO2– was approxi-
mately 5 hours (Figure 8E), indicating that NO2– is not immedi-
ately removed from the luminal side of CF airway epithelia.
Discussion
A hallmark of CF airway disease is the emergence of alginate-over-
producing P. aeruginosa, bacteria that have genotypically and/or 
phenotypically changed from a nonmucoid to mucoid forms and 
are highly resistant to host defenses (8) and antimicrobial therapy 
(7). Clinically, the appearance of this organism is correlated with 
a marked reduction in lung function and nutritional status (39). 
One major mechanism for P. aeruginosa mucoid conversion in CF 
isolates involves mutations in the mucA gene (9). The only other 
known genes that are involved in mucoid conversion include mucB 
(algN) (27), mucD (25), and algW (25), but these mutations are not 
common in clinical isolates.
In this study, we believe that we have discovered the Achilles’ 
heel of the formidable mucoid form of P. aeruginosa, which could 
lead to improved treatment for CF airway disease. Under con-
ditions that mimicked the CF airway mucus, HNO2 was trans-
formed into toxic species that specifically and negatively affected 
viability of mucoid P. aeruginosa. Strikingly, mucA mutant bacte-
ria were very sensitive to species derived from HNO2, which was 
due at least in part to the inherently low NIR and NOR activ-
ity in these strains. In fact, recent work by Firoved et al. (40) 
has shown that mucA mutant bacteria have a markedly reduced 
capacity to remove the NO generated even aerobically from S-
nitrosoglutathione. This is consistent with our results, which 
indicated that NO levels accumulate and remain for greater than 
24 hours. Since MucA is an inner membrane–spanning protein 
and catalytic activities of NIR and NOR reside in the periplas-
mic space, we speculate that the periplasmic portion of MucA 
plays a crucial role in orchestrating the biological function of 
these periplasmic enzymes; indeed, virtually all of the critical 
mutations in the mucA gene predict defects in the periplasmic 
localization of MucA. Studies to define a structural relationship 
between MucA and potential periplasmic proteins are currently 
underway. HNO2 derivatives can damage DNA (41) and modify 
protein micromoieties including Fe-S clusters (42), tyrosine resi-
dues (43), heme (44), and sulfhydryl groups (45). These mecha-
nisms may be involved in the adverse effects on the overall biol-
ogy of mucoid, mucA mutant organisms.
Our mucA sequencing data from 94 different strains from 5 
CF clinics confirm the previous findings of Martin et al. (9) that 
mucoid conversion is mainly caused (87% frequency) by mucA 
mutations (Supplemental Table 1). However, variations exist in 
the mechanisms by which P. aeruginosa undergoes mucoid con-
version (9, 12), and mucoid organisms that have intact mucA 
alleles are being detected, particularly in Europe. The data pre-
sented in this study indicate that only mucA mutant bacteria are 
susceptible to HNO2.
Airway epithelial expression of iNOS does not differ between 
young CF patients and normal children (23). However, as CF 
patients age, expression of iNOS is significantly reduced in CF 
patients (23). This reduced expression of iNOS in chronic CF is 
associated with the emergence of mucoid mucA mutant subpopu-
lations. Currently, however, it is unclear whether conversion to 
the mucoid form, which has limited capacity for NO removal, is 
facilitated by the abnormally low NO or S-nitrosothiol levels in the 
airways of older CF subjects (15).
Our data suggest that 15 mM NO2– kills mucA mutant P. aeru-
ginosa in CF airways at pH 6.5. The NO chemistry of bacteria and 
the CF airways is complex, and several downstream mechanisms 
could account for the effect of HNO2 on mucoid P aeruginosa. 
Our data suggest that NO itself, whether directly or as a pre-
cursor to iron-nitrosyl species, may be involved in the antimi-
crobial effect. Of note, there is evidence that airway acid stress 
characterizes a variety of pulmonary disorders (46), and our 
Figure 6
Effect of HNO2 on killing P. aeruginosa in biofilms and fresh sputum 
isolates. (A) Confocal laser microscopic analysis of anaerobic FRD1 
biofilms. Live cells are stained with syto-9 (green), and dead cells are 
stained with propidium iodide (red). Top (x-y plane) views are pro-
jected from a stack of 125 images taken at 0.4-μm intervals for a total 
of 50 μm. Before staining, 1-day-old anaerobic FRD1 biofilms were 
treated anaerobically with 15 mM NO2– at pH 6.5 and 7.5 for 2 days. 
(B) Biofilms were grown as in A using FRD1/pmucA. (C) Toxicity of 
15 mM NO2– (pH 6.5) toward P. aeruginosa sputum isolates. Viable 
cells in the initial inoculum (black bars) and after a 24-hour anaerobic 
incubation (white bars) are presented in logarithmic scale. CF1–CF4 
are mucoid mucA mutants, and CF5 is nonmuocid and possesses a 
wild-type mucA gene. Each strain was tested in triplicate and the mean 
± SEM is presented. *P < 0.05.
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results are consistent with those of Hunt et al. (47), which sug-
gest that delivery of concentrated NO2– to airway regions with 
low pH likely serves to generate NO and S-nitrosothiols. Indeed, 
NO generated in animal studies of inhaled NO2– may arise from 
HNO2 formation (18). Inhaled NO2– has appeal as a CF therapy 
because it may (a) provide sustained NO release, (b) exploit the 
low pH of the CF airway epithelial mucus layer, (c) selectively 
inhibit growth of mucoid, mucA mutant P. aeruginosa when pro-
tonated to form HNO2, and (d) provide a chemical feedback 
mechanism that maintains the desired NO levels in response 
to its consumption or removal (Figure 4B). Therefore, we hope 
that the data provided in this study stimulates further investiga-
tion. However, it is important to caution that (a) the airway pH 
may not be homogeneous in vivo as excessive regional acidity 
and high HNO2 levels could result in airway injury; (b) excessive 
NO production in the airway could inhibit platelet aggregation, 
potentially aggravating hemoptysis; (c) HNO2 produces carcino-
genic nitrosoamines; (d) the nitrogen redox chemistry in the CF 
airway in vivo is exceptionally complex, and several unexpected 
(and untoward) reactions could result from formation of high 
airway levels of HNO2; (e) for denitrifying organisms that have 
intact NIR and NOR activity (including the Aspergillus species), 
inhaled NO2– could paradoxically promote growth as a nutri-
ent; (f) there are no human data regarding the safety of inhaling 
near-molar quantities of NO2–, which could have adverse local 
and systemic effects; and (g) the precise mechanism by which 
HNO2 affects mucoid P. aeruginosa growth is not known. Still, 
despite these known pitfalls, mucoid P. aeruginosa organisms 
were previously considered impossible to eradicate from the air-
ways of patients with chronic CF lung disease. We believe that 
our data offer hope that effective treatment strategies can be 
designed with the ultimate goal of eradicating this formidable 
foe in CF lung disease.
Methods
Bacterial culture and enzymatic assays. P. aeruginosa strains used in this study 
included nonmucoid strain PAO1 (48), CF isolate FRD1 (49), and sputum 
isolates from CF patients at 5 different North American clinics, totaling 94 
strains (Supplemental Table 1). All procedures using human patients were 
approved by the respective university’s Institutional Review Board with 
respect to informed consent issues. Complementation of FRD1 mucA was 
achieved by transformation with the plasmid ptacmucA (9). Aerobic starter 
cultures were grown in LB (10 g tryptone, 5 g NaCl, and 5 g yeast extract per 
liter) at 37°C. Anaerobic growth was achieved in a Coy anaerobic chamber 
(Coy Laboratory Products). To support anaerobic respiration, KNO3 and/or 
NaNO2 (Sigma-Aldrich) were added to the medium. The pH of the medi-
um was adjusted with 100 mM sodium phosphate (for pH 6.5) or 100 mM 
sodium acetate (for pH 5.5). To enumerate viable bacteria, serial dilutions 
were spotted on LB agar plates. NO2– sensitivity using a filter paper disk 
assay was performed as previously described (31). NAR, NIR, and NOR 
activities were measured as described previously (21). Biofilm staining and 
image acquisition were accomplished as described previously (21).
NO experiments. NO levels were measured polarimetrically using a NO 
electrode system (Model Apollo 400; World Precision Instruments Inc.) 
according to the manufacturer’s instructions. The NO gas exposure study 
was performed as described previously (32).
Measurement of pH in airway secretions. In situ pH measurements of mucopu-
rulent airway secretions from CF airways were made by inserting the tip of a 
pH microelectrode (MI-413; Microelectrodes Inc.) into mucopurulent secre-
tions within lobar, segmental, and subsegmental bronchi of freshly explant-
ed lungs from 9 CF patients. Lungs were removed at the time of organ trans-
plantation. Duplicate readings at 3 different sites per patient were recorded, 
and the mean value from each measurement was used for analysis.
Infection of mouse airways. CD1 mice (n = 8) were infected with approximately 
106 FRD1 or FRD1/pmucA entrapped in agar beads intratracheally as pre-
viously described (33). Following 24 hours’ incubation, mouse lungs were 
instilled with 25 μl of 15 mM NO2– at pH 5.5 (in 0.1 M acetate buffer) or pH 6.5 
Figure 7
Applications of HNO2-mediated killing of mucoid P. aerugi-
nosa to clinical specimens. (A) Killing of FRD1 by NO2– in 
sterile ultrasupernatants of CF airway secretions derived 
from explanted CF lungs. Bacteria were incubated anaero-
bically for 24 hours, and 15 mM NO2– was added. CFUs 
were determined (n = 3) and plotted as the X ± SEM versus 
time. *P < 0.01 versus CFU decrease before adding NO2–. 
(B) NO generation in CF ASL by 15 mM NO2–. Except for 
the media and pH, experimental conditions were identical 
to those used in Figure 4B. (C) Effects of NO2– on killing of 
FRD1 and FRD1/pmucA in mouse lungs. CD1 mice were 
infected with FRD1 or FRD1/pmucA as described in Meth-
ods. Infected mice were treated with buffer (black bars) and 
buffered NO2– (white bars) daily, and viable bacteria from 
the lung homogenates were enumerated. n = 8 per group. 
*P < 0.01 versus buffer alone. (D) Effects of long-term 
NO2– treatment on killing of FRD1 in mouse lungs. Another 
group of FRD1-infected mice were treated daily with buffer 
(–, 50 mM sodium phosphate, pH 6.5) or buffer with 15 mM 
NO2– (+) for 16 days (n = 8 per group). Organisms surviving 
treatment with buffer and NO2– were shown in logarithmic 
scale. *P < 0.01 versus buffer alone. (E) CI experiments 
with 106 FRD1 and FRD1/pmucA intratracheally instilled 
into CD1 mouse airways and incubated for 6 days prior to 
harvesting of mouse lungs and enumeration of CFUs after 
homogenization.
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(in 0.1 M phosphate buffer) intranasally twice daily. On the fifth day mice 
were sacrificed, and the viable bacteria from serially diluted lung homogenates 
were enumerated. One group of FRD1-infected mice was treated with 15 mM 
NO2– at pH 6.5 as described above for 16 days to examine whether bacteria 
develop resistance after prolonged exposure to NO2–. All animal studies were 
performed in accordance with the protocols approved by the Animal Care 
Committee of the University of Cincinnati College of Medicine.
In vivo competition assays. In vivo competition assays between mucoid mucA 
mutant strain FRD1 and FRD1/pmucA embedded in agar beads were carried 
out by infecting CD1 mice (n = 6) intratracheally (2 × 105 bacteria) with a 1:1 
ratio of each strain as previously described (50). Twenty-four hours after infec-
tion, mouse lungs were instilled with 25 μl of PBS at pH 6.5 or PBS containing 
15 mM NaNO2 at pH 6.5 twice daily for 4 days. Infected lungs were recovered 
after 6 days for bacterial load and CI calculations. The CI was defined as the 
output ratio of mutant to wild-type bacteria divided by the input ratio of 
mutant to wild-type bacteria (51). Thus, if a mutant strain is as competitive 
as its isogenic wild-type parent, a value of 1 will be achieved. A CI of less than 
1 implies that the mutant is not as competitive as the wild-type strain.
Biological properties of airway epithelia in response to NO2–. Primary bronchial 
epithelial cultures, grown on Transwell Col (1.13 cm2 surface area) permeable 
supports (52), were mounted in Ussing chambers (ADInstruments Co.), and 
bioelectric properties were analyzed as previously 
described (53). IL-8 concentrations in basolateral 
media were measured using commercially available 
antibody pairs (R&D Systems) according to the 
manufacturer’s instructions. Cellular cytotoxicity 
was assessed by comparing release of lactate dehydro-
genase into the basolateral media of cultured airway 
epithelial cell preparations treated apically with vary-
ing NO2– concentrations. Lactate dehydrogenase was 
measured using a commercially available spectropho-
tometric assay kit (BioVision Research Products). For 
experiments measuring transepithelial water flux, 
culture preparations were treated apically with 100 μl 
of Krebs bicarbonate Ringer solution containing 2% 
blue dextran (a cell-impermeable volume marker dye) 
supplemented with 15 mM NO2–. After 24 hours, 
microaliquots (2–5 μl) of apical liquid were collected 
and stored at –20°C until analyzed. Blue dextran con-
centrations were measured spectrophotometrically. 
To determine the half life of NO2– on the surface of 
cultured airway epithelia, NO2– levels were measured 
by the Griess reaction (54), and the percent rate of 
NO2– removal was calculated.
Preparation of sterile ultrasupernatants of CF airway 
secretions. Purulent secretions were harvested from the 
airways of CF lungs that were removed at the time of 
transplantation. Purulent secretions were centrifuged 
(100,000 g for 1 hour) and passed through a sterile fil-
ter (0.22 μm, Costar 8110 mStar; Millipore).
Statistics. Results are presented as mean ± SEM. 
Student’s t test (2-tailed, unequal variance, for 
Figures 1–6) and ANOVA (Figure 7) were used to 
analyze the significance of differences between exper-
imental groups. A P value less than 0.05 was consid-
ered statistically significant. Kinetic modeling was 
carried out using the INTKIN computer program, 
developed at the Brookhaven National Laboratory 
by Harold A. Schwarz (55). The necessary rate data 
were obtained from the literature (56).
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Figure 8
Effect of NO2– on function of cultured human airway epithelia. (A) Culture preparations of 
human CF airway epithelium (duplicate preparations, n = 3) were exposed apically to 2 μl of 
varying concentrations of NO2–. After 24 hours, lactate dehydrogenase activity in the baso-
lateral media was measured to monitor cytotoxicity. (B) CF airway epithelial cultures were 
mounted in Ussing chambers and treated with 2 μl of liquid containing NO2– at varying concen-
trations. Transepithelial short circuit current (Isc, in μA/cm2) was measured to monitor change 
in bioelectric properties. (C) CF airway epithelial cultures (triplicate preparations, n = 4), were 
treated luminally with 100 μl Krebs bicarbonate Ringer buffer containing 2% blue dextran and 
supplemented with either 15 mM NaCl (control) or NO2– for 24 hours. Transepithelial water 
flux (Jv) was calculated by measuring blue dextran concentration optically after 24 hours in 
microaliquots of sampled luminal liquid. (D) IL-8 release assay using primary cultures of CF 
airway epithelia (n = 4) exposed to 15 mM NO2– compared with control cultures. (E) Deter-
mination of NO2– half life on the surface of airway epithelia. The 3 different concentrations of 
NO2– were applied to airway epithelial cell monolayers, and NO2– levels were assayed at the 
indicated intervals (n = 3 for each measurement). P = NS for all comparisons (ANOVA).
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